pneumonia
one
common
caus
death
infecti
diseas
worldwid
common
fatal
infect
acquir
hospit
despit
advanc
prevent
strategi
antibiot
therapi
intens
care
signific
improv
mortal
rate
still
lack
high
mortal
larg
due
limit
current
clinic
practic
laboratori
test
delay
time
adequ
antibiot
therapi
recent
year
mani
indic
biomark
present
scenario
infecti
pathogen
invad
bodi
biomark
reflect
specif
biolog
respons
infect
report
demonstr
abil
facilit
diagnosi
risk
stratif
manag
pneumonia
review
provid
schemat
overview
new
potenti
biomark
base
categori
microorgan
deriv
inflamm
mediat
inflamm
respons
protein
stresssens
protein
addit
approach
identifi
new
biomark
also
briefli
introduc
although
current
biomark
sole
achiev
definit
diagnosi
mani
complement
rather
replac
outright
routin
clinic
practic
improv
decisionmak
process
regard
pneumonia
acquir
outsid
hospit
hap
describ
infect
acquir
hospit
set
vap
subtyp
hap
occur
receiv
mechan
ventil
nhap
defin
infect
acquir
extendedcar
facil
unit
state
estim
million
patient
diagnos
cap
annual
million
requir
hospit
admiss
mortal
rate
cap
outpati
rang
patient
requir
hospit
much
patient
requir
admiss
intens
care
unit
icu
although
clinic
present
often
similar
pneumonia
also
classifi
typic
atyp
type
accord
differ
pathogen
typic
type
pneumonia
usual
caus
bacteria
streptococcu
staphylococcu
atyp
type
caus
influenza
viru
mycoplasma
chlamydia
legionella
adenoviru
unidentifi
microorgan
ideal
earli
definit
diagnosi
achiev
verifi
specif
pathogen
involv
subsequ
treatment
specif
antibiot
improv
prognosi
pneumonia
howev
rapid
accur
diagnosi
pneumonia
remain
challeng
common
clinic
symptom
pneumonia
patient
includ
cough
fever
chill
fatigu
dyspnea
rigor
pleurit
chest
pain
depend
variou
type
pathogen
involv
pneumonia
may
accompani
differ
featur
accord
clinic
guidelin
gold
standard
diagnos
pneumonia
involv
use
chest
radiographi
detect
presenc
pulmonari
infiltr
howev
chest
radiographi
sensit
enough
detect
specif
pulmonari
infiltr
earli
cours
diseas
onethird
possibl
pneumonia
diagnos
may
miss
use
chest
radiographi
addit
certain
chronic
diseas
congest
heart
failur
chronic
obstruct
pulmonari
diseas
malign
also
interfer
result
laboratori
test
includ
leukocyt
count
sputum
gram
stain
set
blood
cultur
urin
antigen
also
help
provid
definit
diagnosi
guid
therapeut
decis
make
howev
result
test
patient
suspect
cap
vari
uncertain
qualiti
specimen
use
antimicrobi
drug
posit
blood
cultur
may
correl
sever
ill
outcom
uncertainti
timeconsum
limit
may
obscur
accur
diagnos
delay
begin
treatment
therefor
innov
approach
identifi
indic
biolog
state
pneumonia
eager
achiev
term
biomark
defin
biolog
molecul
found
blood
bodi
fluid
tissu
sign
normal
abnorm
process
condit
diseas
biomark
may
use
see
well
bodi
respond
treatment
diseas
condit
accord
definit
qualifi
biomark
pneumonia
use
accomplish
least
one
follow
task
perform
rapid
accur
diagnosi
less
affect
diseas
identifi
type
pathogen
microorgan
specif
antibiot
treatment
reflect
statu
success
prognosi
therapi
remain
elev
infecti
stimulu
consequ
potenti
biomark
pneumonia
exist
specif
biolog
respons
infect
scenario
infecti
pathogen
invad
host
bodi
noteworthili
potenti
marker
pneumonia
also
describ
sepsi
therefor
biomark
pneumonia
fall
four
categori
microorgan
deriv
inflamm
mediat
inflamm
respons
protein
stresssens
protein
tabl
progress
pneumonia
pathogen
bacteria
undergo
host
respiratori
colon
growth
detect
character
perform
convent
laboratori
test
although
method
highli
specif
result
affect
usag
antimicrobi
drug
sensit
poor
applic
polymeras
chain
reaction
pcr
speciesspecif
gene
conserv
bacteri
dna
sequencebas
diagnost
test
develop
contrast
neg
sputum
cultur
sampl
patient
infect
streptococcu
pneumonia
receiv
antibiot
still
accur
evalu
appli
pcr
examin
use
realtim
rt
pcr
techniqu
reduc
time
consumpt
associ
cultur
method
permit
earli
diagnosi
prospect
studi
denmark
quantit
multiplex
pcr
method
evalu
detect
pneumonia
haemophilu
influenza
neisseria
meningitidi
bronchoalveolar
lavag
fluid
balf
cerebrospin
fluid
csf
sensit
specif
pneumonia
h
influenza
reach
cutoff
genom
copiesml
clinic
posit
previou
studi
patient
taken
antibiot
prior
sampl
pneumonia
infect
h
influenza
infect
could
detect
use
pcr
wherea
respect
could
detect
cultur
addit
identifi
pneumonia
n
meningitidi
csf
achiev
sensit
specif
pathogen
detect
pcr
found
use
cultur
method
vice
versa
suggest
pcr
provid
addit
inform
compar
current
cultur
method
pcr
result
may
show
exist
specif
infecti
pathogen
howev
consid
ill
pneumonia
vap
main
infect
acquir
icu
use
antibiot
microbiolog
flora
associ
vap
encompass
multidrugresist
bacteria
vap
case
caus
gramneg
bacteria
contain
abund
endotoxin
outer
membran
concentr
endotoxin
balf
exhibit
relationship
quantiti
gram
neg
bacteria
vap
amount
greater
equal
euml
use
distinguish
patient
gramneg
posit
bacteri
pneumonia
sensit
specif
posit
predict
valu
neg
predict
valu
determin
concentr
endotoxin
balf
facilit
diagnosi
gramneg
pneumonia
antibiot
therapi
although
gram
stain
balf
provid
inform
infecti
pathogen
invad
begin
grow
host
rapidli
releas
cohort
inflammatori
cytokin
interleukin
il
tumor
necrosi
factor
tnf
respons
infect
howev
proinflammatori
cytokin
met
criteria
clinic
applic
short
halflif
low
specif
well
exist
natur
inhibitori
factor
serum
studi
patient
cap
detect
patient
admiss
decreas
significantli
thereaft
present
prognost
marker
correl
acut
physiolog
chronic
health
evalu
ii
apach
ii
score
admiss
base
evalu
high
level
increas
risk
mortal
cap
conwaymorri
et
al
found
balf
granulocytemacrophag
colonystimul
factor
gmcsf
macrophag
inflammatori
protein
mip
significantli
higher
vap
patient
patient
balf
lower
pgml
posttest
probabl
vap
wherea
level
greater
ngml
correspond
probabl
vap
present
addit
cytokin
could
detect
within
h
show
signific
impact
clinic
decis
make
innat
immun
system
first
line
host
defens
pathogen
compris
cellular
solubl
compart
major
compon
solubl
compart
pattern
recognit
protein
demonstr
abil
recogn
pathogenassoci
molecular
pattern
pamp
collectin
ficolin
pentraxin
initi
immun
respons
pentraxin
famili
acutephas
reactant
highli
conserv
biolog
class
arachnid
mammal
base
primari
structur
pentraxin
divid
two
group
short
long
pentraxin
creactiv
protein
crp
serum
amyloid
p
compon
sap
prototyp
short
pentraxin
long
pentraxin
prototyp
long
pentraxin
plasma
pentraxin
bare
detect
normal
condit
rapidli
increas
counteract
infect
repres
invalu
diagnost
indic
pneumonia
crp
first
identifi
serum
pneumonia
patient
crp
observ
disappear
recov
patient
detect
healthi
peopl
presenc
calcium
crp
recogn
bind
sever
pamp
present
bacteria
fungi
parasit
becom
involv
clearanc
microorgan
crp
synthes
hepatocyt
induct
although
cytokin
also
involv
healthi
human
adult
concentr
crp
lower
mgl
secret
crp
start
h
stimul
doubl
everi
h
reach
maximum
valu
h
exist
stimuli
crp
product
still
evalu
even
refer
valu
stimulu
remov
crp
valu
fall
rapidli
halflif
h
serum
crp
report
studi
regard
role
identifi
patient
pneumonia
elev
crp
level
sensit
specif
predict
pneumonia
diagnost
perform
superior
white
blood
cell
count
erythrocyt
sediment
rate
prospect
hospitalbas
cap
studi
serum
crp
level
elev
mgl
patient
mgl
patient
day
hospit
admiss
patient
receiv
antibiot
prior
hospit
admiss
exhibit
significantli
lower
crp
level
radiolog
confirm
pneumonia
specif
crp
cutoff
valu
mgl
predict
pneumonia
reach
serum
crp
valu
significantli
higher
cap
patient
compar
healthi
control
suspect
cap
patient
high
crp
valu
suggest
sever
determin
appropri
inpati
care
addit
serum
crp
level
demonstr
greatli
increas
sever
bacteri
infect
modestli
increas
viral
respiratori
tract
infect
high
crp
valu
especi
present
patient
pneumonia
caus
pneumonia
legionella
pneumophila
singl
paramet
crp
concentr
greater
mgl
appear
highli
specif
bacteri
infect
combin
marker
improv
diagnost
accuraci
differenti
patient
bacteri
viral
lower
respiratori
tract
infect
lrti
compar
crp
alon
contrast
previou
studi
infer
crp
lack
specif
bacteri
infect
high
crp
level
could
due
inflammatori
condit
serum
level
crp
may
larg
depend
statu
system
inflammatori
respons
rather
direct
outcom
diseas
gener
characterist
patient
age
sex
may
also
strongli
influenc
serum
crp
valu
altern
assess
result
rel
variat
may
provid
inform
cours
infect
absolut
variat
serial
measur
crp
patient
may
repres
progress
clinic
cours
also
help
assess
respons
antibiot
therapi
cohort
studi
hap
patient
crp
ratio
day
admiss
day
could
separ
good
poor
respons
mortal
rate
respect
multicent
prospect
observ
studi
communityacquir
sepsi
et
al
indic
earli
day
onward
crp
concentr
survivor
decreas
level
significantli
lower
nonsurvivor
et
al
also
suggest
h
antibiot
therapi
crp
valu
sever
cap
survivor
decreas
admiss
day
patient
consist
decreas
crp
ratio
usual
favor
respons
antibiot
therapi
long
pentraxin
similar
short
pentraxin
acutephas
reactant
play
crucial
role
solubl
innat
immun
pattern
recognit
receptor
activ
innat
immun
howev
exhibit
differ
featur
short
pentraxin
structur
gene
locat
cellular
sourc
induc
stimuli
ligand
recognit
structur
relat
crp
sap
contain
unrel
long
aminotermin
domain
coupl
carboxyltermin
pentraxin
domain
gene
short
pentraxin
locat
chromosom
wherea
locat
chromosom
unlik
crp
produc
liver
stimul
secondari
cytokin
induc
tolllik
receptor
engag
primari
cytokin
variou
cell
type
particularli
mononuclear
phagocyt
dendrit
cell
fibroblast
endotheli
cell
epitheli
cell
induc
product
taken
togeth
find
impli
serum
level
may
directli
reflect
sever
infect
less
affect
inflammatori
condit
level
low
normal
condit
ngml
human
examin
sever
clinic
set
infecti
diseas
thu
reveal
correl
sever
mortal
cohort
studi
consecut
critic
ill
patient
admit
icu
system
inflammatori
respons
syndrom
sepsi
septic
shock
show
elev
gradient
system
inflammatori
respons
syndrom
septic
shock
level
correl
clinic
score
also
reflect
sever
diseas
higher
level
associ
unfavor
outcom
sever
leptospirosi
patient
plasma
level
also
associ
sever
mortal
diseas
crp
level
could
use
differenti
sever
severest
case
studi
patient
meningococc
diseas
high
plasma
concentr
seen
admiss
correl
patient
shock
wherea
crp
level
admiss
neg
correl
level
correl
mortal
day
spent
icu
bacteremia
patient
valu
day
markedli
higher
nonsurvivor
compar
survivor
show
sensit
specif
fatal
diseas
cutoff
level
ngml
show
higher
prognost
valu
compar
crp
prognost
stratif
bacteremia
patient
recent
data
cap
crp
level
decreas
antibiot
treatment
plasma
concentr
correl
sever
cap
length
hospit
stay
calcitonin
gene
peptid
includ
procalcitonin
pct
ct
generel
peptid
adrenomedullin
superfamili
endocrin
cellproduc
hormon
system
activ
classic
product
calcitonin
gene
peptid
mainli
carri
neuroendocrin
cell
addit
calcitonin
gene
peptid
also
express
variou
parenchym
cell
releas
microbi
toxin
proinflammatori
cytokin
stimul
system
releas
calcitonin
gene
peptid
occur
cytokinelik
manner
consid
prototyp
hormokin
serum
level
calcitonin
gene
peptid
may
appli
indic
statu
infect
procalcitonin
procalcitonin
pct
thyroid
parafollicular
cellproduc
prohormon
kda
low
serum
ngml
healthi
peopl
wherea
circul
pct
level
primarili
deriv
nonthyroid
tissu
increas
sever
patient
sepsi
process
microbi
infect
lipopolysaccharid
lp
promot
calci
gene
express
increas
releas
pct
circul
parenchym
tissu
liver
peripher
blood
mononuclear
cell
septic
stimulu
pct
protein
product
parenchym
cell
detect
h
halflif
approxim
h
addit
product
pct
may
also
markedli
increas
noninfecti
condit
trauma
surgeri
burn
heat
stroke
reject
transplant
pct
level
attenu
cytokin
releas
respons
viral
infect
prohormon
requir
posttransl
process
form
matur
type
hormon
may
demonstr
distinct
biolog
activ
hamster
septic
model
concentr
pct
rapidli
evalu
peak
h
induct
sepsi
exogen
pct
significantli
increas
mortal
rate
prophylact
blockad
pct
attenu
lethal
effect
sepsi
increas
circul
pct
level
may
exacerb
mortal
rate
diminish
product
pct
increas
surviv
infer
pct
may
play
detriment
role
system
inflamm
addit
chang
circul
pct
level
may
repres
sever
infect
may
use
prognost
marker
therefor
circul
pct
level
examin
monitor
progress
sever
sepsi
septic
shock
respons
antimicrobi
therapi
two
commerci
pct
detect
assay
demonstr
high
sensit
low
detect
limit
fast
readout
current
avail
sever
studi
report
valu
use
pct
level
manag
cap
suggest
rise
pct
facilit
earli
identif
risk
mortal
critic
ill
patient
result
two
random
prospect
studi
cap
patient
total
patient
suspect
lower
respiratori
tract
infect
pct
present
higher
diagnost
accuraci
differenti
cap
diagnos
crp
total
leukocyt
count
pct
level
also
demonstr
higher
accuraci
predict
bacteremia
sever
cap
vap
cohort
studi
sequenti
measur
pct
crp
level
pct
crp
level
significantli
higher
patient
confirm
vap
pct
demonstr
higher
accuraci
howev
pct
crp
level
balf
help
differenti
confirm
nonconfirm
vap
addit
discrimin
accur
diagnosi
pneumonia
pct
level
demonstr
prognost
valu
cap
patient
studi
pct
crp
wbc
score
cap
patient
determin
admiss
followedup
day
ascertain
mortal
similar
prognost
accuraci
score
show
pct
level
admiss
predict
sever
outcom
cap
pct
level
show
higher
prognost
accuraci
crp
leukocyt
count
provid
independ
identif
patient
low
risk
death
use
pct
level
christcrain
et
al
reduc
antibiot
exposur
patient
cap
median
day
random
trial
investig
guidanc
antibiot
treatment
durat
cap
dynam
level
pct
may
present
guid
choic
durat
antibiot
therapi
proadrenomedullin
adrenomedullin
gene
encod
acid
preprohormon
gener
acid
peptid
proam
remov
signal
peptid
process
form
activ
peptid
pamp
defin
pamp
express
mani
tissu
includ
adren
medulla
atrium
lung
pancrea
small
intestin
addit
potent
vasodil
activ
modul
complement
activ
perform
bactericid
activ
cultur
vascular
smoothmuscl
endotheli
cell
product
larg
induc
lp
tnf
stimul
contrast
also
suppress
secret
gene
transcript
swiss
fibroblast
regul
product
may
involv
feedback
loop
inflammatori
respons
serum
level
might
reflect
sever
infect
howev
rapidli
clear
circul
determin
level
proam
altern
repres
level
rapidli
degrad
activ
peptid
proam
level
help
individu
risk
assess
outcom
predict
sepsi
previou
studi
demonstr
median
proam
level
nm
healthi
peopl
nm
sepsi
nm
sever
sepsi
nm
patient
septic
shock
admiss
also
significantli
higher
nonsurvivor
survivor
prospect
observ
studi
proam
level
correl
sever
cap
could
predict
mortal
admiss
combin
psi
proam
level
increas
prognost
accuraci
predict
risk
stratif
cap
patient
pediatr
cap
patient
proam
level
also
relat
develop
complic
hospit
although
proam
level
help
distinguish
sever
risk
cap
show
high
coverag
concentr
rang
cutoff
valu
pneumonia
still
need
evalu
trigger
receptor
express
myeloid
trem
member
immunoglobulin
superfamili
receptor
express
high
level
neutrophil
monocyt
infiltr
human
tissu
infect
bacteria
microbi
sepsi
patient
anim
model
lpsinduc
shock
trem
upregul
periton
neutrophil
silenc
trem
vivo
fecal
periton
mous
model
blunt
inflammatori
respons
increas
mortal
effect
occur
impair
bacteri
clearanc
relat
mark
inhibit
neutrophil
oxid
burst
rais
trem
express
level
may
promot
neutrophil
activ
elimin
microorgan
trem
bind
ligand
activ
associ
adapt
protein
induc
secret
inflammatori
cytokin
monocyt
chemotact
induc
neutrophil
degranul
respons
infect
trem
highli
express
neutrophil
caus
staphylococcu
aureu
bartonella
hensela
aspergillu
fumigatu
infect
phenomenon
observ
sampl
patient
noninfecti
inflammatori
condit
indic
upregul
membranebound
solubl
form
strem
trem
may
specif
involv
infecti
diseas
increas
express
trem
found
infiltr
neutrophil
monocyt
strem
level
balf
may
diagnost
valu
pneumonia
prospect
studi
suspect
cap
vap
patient
presenc
balf
strem
accur
clinic
find
laboratori
valu
identifi
presenc
bacteri
fungal
pneumonia
suggest
balf
strem
may
serv
independ
predictor
pneumonia
contrast
studi
conduct
evalu
use
strem
balf
icu
patient
rapid
diagnost
test
vap
strem
level
balf
could
discrimin
vap
although
confirm
vap
patient
exhibit
higher
concentr
strem
balf
unconfirm
vap
patient
anoth
prospect
cohort
studi
mean
strem
concentr
higher
confirm
vap
patient
find
lack
statist
signific
patient
alveolar
hemorrhag
greatest
valu
strem
concentr
cutoff
valu
strem
greater
pgml
yield
diagnost
sensit
specif
definit
vap
addit
measur
balf
serum
level
strem
also
report
signific
elev
pneumonia
copd
asthma
exacerb
level
strem
may
correl
inflamm
condit
appear
less
accur
sole
marker
pneumonia
therefor
strem
level
must
combin
marker
accur
evalu
sepsi
innat
immun
system
releas
multipl
inflamm
mediat
relat
protein
respons
pathogen
period
uncontrol
secret
mediat
outgrowth
pathogen
releas
endotoxin
caus
detriment
physiolog
stress
tissu
edema
organ
failur
shock
affect
vital
sign
neuroendocrin
system
hypothalamopituitaryadren
hpa
axi
regul
mani
physic
process
appropri
react
stress
releas
corticotropinreleas
hormon
crh
costimul
crh
anoth
stressor
arginin
vasopressin
avp
induc
adrenocorticotrop
hormon
acth
secret
control
adren
cortex
produc
cortisol
cascad
process
circul
level
avp
cortisol
may
use
indic
sever
particular
ill
level
circul
avp
difficult
measur
releas
pulsatil
manner
unstabl
plasma
bound
platelet
activ
avp
deriv
larger
precursor
peptid
preprovasopressin
consist
signal
peptid
avp
neurophysin
ii
copeptin
copeptin
glycosyl
peptid
leucinerich
core
segment
simultan
releas
avp
precursor
process
consid
altern
indic
avp
concentr
addit
copeptin
stabl
day
blood
withdraw
quickli
easili
measur
increas
copeptin
level
shown
posit
associ
copeptin
sever
outcom
ill
sepsi
hemorrhag
shock
stroke
studi
lower
respiratori
tract
infect
lrti
patient
copeptin
level
significantli
increas
lrti
patient
highest
level
copeptin
observ
patient
cap
copeptin
level
also
associ
sever
cap
nonsurvivor
exhibit
significantli
higher
copeptin
level
admiss
copeptin
level
power
predictor
shortterm
longterm
risk
stratif
patient
cap
addit
cap
copeptin
level
also
indic
sever
mortal
vap
circul
copeptin
level
repres
accur
marker
earli
risk
stratif
appli
manag
pneumonia
patient
activ
hpa
axi
character
increas
cortisol
level
thu
indic
cortisol
copeptin
essenti
surviv
parallel
degre
stress
major
circul
cortisol
human
serum
bound
protein
howev
free
cortisol
rather
proteinbound
fraction
respons
physiolog
function
although
total
cortisol
level
accur
reflect
intens
activ
hpa
axi
free
cortisol
concentr
still
repres
indic
critic
ill
patient
total
free
form
cortisol
report
increas
increas
sever
cap
observ
significantli
higher
nonsurvivor
cortisol
show
potenti
predict
mortal
critic
diseas
cap
patient
independ
clinic
score
inflammatori
biomark
mention
potenti
biomark
pneumonia
may
exist
scenario
infecti
pathogen
invad
bodi
reflect
specif
biolog
respons
infect
addit
pneumonia
marker
discuss
biomark
proatrial
natriuret
peptid
btype
natriuret
peptid
red
cell
distribut
width
examin
demonstr
abil
improv
diagnosi
prognosi
pneumonia
advanc
proteom
research
develop
gel
electrophoresi
mass
spectrometri
bioinformat
analysi
global
protein
analysi
appli
inventori
identifi
potenti
pneumonia
marker
deduct
cost
higher
resolut
fast
perform
proteom
technolog
use
stage
larg
clinic
intervent
trial
yip
et
al
appli
protein
chip
array
profil
analysi
identifi
biomark
might
use
monitor
clinic
cours
sever
acut
respiratori
syndrom
patient
identifi
concentr
serum
amyloid
protein
short
pentraxin
biomark
potenti
use
monitor
extent
pneumonia
research
group
taiwan
appli
gel
electrophoresi
mass
spectrometri
identifi
differenti
level
haptoglobin
immunoglobulin
kappa
chain
apolipoprotein
ai
transthyretin
plasma
protein
profil
children
differ
sever
pneumococc
pneumonia
addit
proteom
studi
metabolom
rapidli
expand
field
identifi
quantifi
chang
level
metabolit
within
biofluid
blood
saliva
urin
studi
aim
compar
pneumonia
microbemedi
pneumonia
urinari
metabolom
profil
pneumococc
pneumonia
patient
significantli
differ
patient
viral
bacteri
form
pneumonia
result
metabolom
analysi
sever
childhood
pneumonia
gambia
also
clearli
distinguish
sever
pneumonia
patient
commun
control
identifi
metabolit
relat
host
respons
infect
antioxid
inflammatori
antimicrobi
pathway
well
energi
metabol
find
indic
nmrbase
analysi
metabolit
urin
may
provid
new
inform
diagnosi
etiolog
pneumonia
pneumonia
lead
caus
sever
sepsi
present
cohort
process
entri
pathogen
host
defens
respons
potenti
biomark
may
provid
differ
clinic
valu
detect
pneumonia
accord
origin
biolog
featur
first
identifi
microorgan
deriv
help
ascertain
etiolog
pneumonia
second
evalu
inflamm
mediat
respons
protein
provid
inform
degre
immun
combat
pulmonari
pathogen
caus
diseas
facilit
pneumonia
manag
final
circul
stresssens
protein
reflect
condit
ill
use
stratifi
risk
predict
prognosi
howev
due
heterogen
pneumonia
patient
vari
age
sex
comorbid
condit
develop
complic
clinic
cutoff
valu
potenti
biomark
must
determin
conclus
implic
biomark
consid
complementari
routin
clinic
laboratori
featur
improv
decis
make
regard
pneumonia
